DNA methylation changes correlate with gleason score and tumor stage in prostate cancer

DNA and Cell Biology

Volumn 31, Issue 2, 2012, Pages 187-192

  Delgado Cruzata, Lissette ^a   Hruby, Gregory W ^b   Gonzalez, Karina ^a   McKiernan, James ^b   Benson, Mitchel C ^b   Santella, Regina M ^a   Shen, Jing ^a  

^a Columbia University ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; DNA; GLUTATHIONE TRANSFERASE P1; PROTEIN P16;

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DNA METHYLATION; GENE; GLEASON SCORE; HUMAN; LINE 1 GENE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PYROSEQUENCING;

AGED; CARCINOMA; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEOXYRIBONUCLEASE I; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 84856721943     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1311     Document Type: Article

References (43)

1. Ahmed, H. (2010). Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2010, 17-33.
2. Andriole, G.L., Crawford, E.D., Grubb, R.L., III, Buys, S.S., Chia, D., Church, T.R., Fouad, M.N., Gelmann, E.P., Kvale, P.A., Reding, D.J., Weissfeld, J.L., Yokochi, L.A., O'Brien, B., Clapp, J.D., Rathmell, J.M., Riley, T.L., Hayes, R.B., Kramer, B.S., Izmirlian, G., Miller, A.B., Pinsky, P.F., Prorok, P.C., Gohagan, J.K., and Berg, C.D. (2009). Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360, 1310-1319.
3. Baden, J., Green, G., Painter, J., Curtin, K., Markiewicz, J., Jones, J., Astacio, T., Canning, S., Quijano, J., Guinto, W., Leibovich, B.C., Nelson, J.B., Vargo, J., Wang, Y., and Wuxiong, C. (2009). Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol 182, 1186-1193.
4. Bastian, P.J., Ellinger, J., Wellmann, A., Wernert, N., Heukamp, L.C., Muller, S.C., and von Ruecker, A. (2005). Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 11, 4097-4106. (Pubitemid 40791574)
5. Bollati, V., Baccarelli, A., Hou, L., Bonzini, M., Fustinoni, S., Cavallo, D., Byun, H.M., Jiang, J., Marinelli, B., Pesatori, A.C., Bertazzi, P.A., and Yang, A.S. (2007). Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res 67, 876-880.
6. Brawley, O.W., Ankerst, D.P., and Thompson, I.M. (2009). Screening for prostate cancer. CA Cancer J Clin 59, 264-273.
7. Chu, D.C., Chuang, C.K., Fu, J.B., Huang, H.S., Tseng, C.P., and Sun, C.F. (2002). The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J Urol 167, 1854-1858.
8. Chuang, C.K., Chu, D.C., Tzou, R.D., Liou, S.I., Chia, J.H., and Sun, C.F. (2007). Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect Prev 31, 59-63.
9. Cook, E.D., and Nelson, A.C. (2011). Prostate cancer screening. Curr Oncol Rep 13, 57-62.
10. Deng, D., Liu, Z., and Du, Y. (2010). Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. Adv Genet 71, 125-176.
11. Dobosy, J.R., Roberts, J.L., Fu, V.X., and Jarrard, D.F. (2007). The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 177, 822-831. (Pubitemid 46223571)
12. Epstein, J.I. (2010). An update of the Gleason grading system. J Urol 183, 433-440.
13. Hoque, M.O. (2009). DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 9, 243-257.
14. Hoque, M.O., Topaloglu, O., Begum, S., Henrique, R., Rosenbaum, E., Van Criekinge, W., Westra, W.H., and Sidransky, D. (2005). Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23, 6569-6575. (Pubitemid 46190250)
15. Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., Pihl, C.G., Stranne, J., Holmberg, E., and Lilja, H. (2010). Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11, 725-732.
16. Jacobson, J.S., Begg, M.D., Wang, L.W., Wang, Q., Agarwal, M., Norkus, E.P., Singh, V.N., Young, T.L., Yang, D., and Santella, R.M. (2000). Effects of a six-month intervention on DNA damage in heavy smokers. Cancer Epidemiol Biomark Prevent 9, 1303-1311. (Pubitemid 32044798)
17. Jarrard, D.F., Bova, G.S., Ewing, C.M., Pin, S.S., Nguyen, S.H., Baylin, S.B., Cairns, P., Sidransky, D., Herman, J.G., and Isaacs, W.B. (1997). Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19, 90-96. (Pubitemid 27231483)
18. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer Statistics, 2010. CA Cancer J Clin 60, 277-300.
19. Jeronimo, C., Henrique, R., Hoque, M.O., Mambo, E., Ribeiro, F.R., Varzim, G., Oliveira, J., Teixeira, M.R., Lopes, C., and Sidransky, D. (2004). A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10, 8472-8478. (Pubitemid 40053412)
20. Jung, K., Fleischhacker, M., and Rabien, A. (2010). Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 411, 1611-1624.
21. Kang, G.H., Lee, S., Lee, H.J., and Hwang, K.S. (2004). Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 202, 233-240. (Pubitemid 38208661)
22. Levenson, V.V. (2010). DNA methylation as a universal biomarker. Expert Rev Mol Diagn 10, 481-488.
23. Li, L.C. (2007). Epigenetics of prostate cancer. Front Biosci 12, 3377-3397.
24. Loeb, S., Vonesh, E.F., Metter, E.J., Carter, H.B., Gann, P.H., and Catalona, W.J. (2010). What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 29, 464-467.
25. Maruyama, R., Toyooka, S., Toyooka, K.O., Virmani, A.K., Zochbauer-Muller, S., Farinas, A.J., Minna, J.D., McConnell, J., Frenkel, E.P., and Gazdar, A.F. (2002). Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8, 514-519. (Pubitemid 34193971)
26. Meiers, I., Shanks, J.H., and Bostwick, D.G. (2007). Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology 39, 299-304. (Pubitemid 46897603)
27. Nelson, W.G., Yegnasubramanian, S., Agoston, A.T., Bastian, P.J., Lee, B.H., Nakayama, M., and De Marzo, A.M. (2007). Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 12, 4254-4266.
28. Phe, V., Cussenot, O., and Roupret, M. (2010). Methylated genes as potential biomarkers in prostate cancer. BJU Int 105, 1364-1370.
29. Pinzani, P., Salvianti, F., Pazzagli, M., and Orlando, C. (2010). Circulating nucleic acids in cancer and pregnancy. Methods 50, 302-307.
30. Reibenwein, J., Pils, D., Horak, P., Tomicek, B., Goldner, G., Worel, N., Elandt, K., and Krainer, M. (2007). Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 67, 427-432. (Pubitemid 46341084)
31. Roupret, M., Hupertan, V., Catto, J.W., Yates, D.R., Rehman, I., Proctor, L.M., Phillips, J., Meuth, M., Cussenot, O., and Hamdy, F.C. (2008). Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 122, 952-956.
32. Roupret, M., Hupertan, V., Yates, D.R., Catto, J.W., Rehman, I., Meuth, M., Ricci, S., Lacave, R., Cancel-Tassin, G., de la, T.A., Rozet, F., Cathelineau, X., Vallancien, G., Hamdy, F.C., and Cussenot, O. (2007). Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 13, 1720-1725. (Pubitemid 46952937)
33. Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L.J., Recker, F., Berenguer, A., Maattanen, L., Bangma, C.H., Aus, G., Villers, A., Rebillard, X., van der, K.T., Blijenberg, B.G., Moss, S.M., de Koning, H.J., and Auvinen, A. (2009). Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360, 1320-1328.
34. Schulz, W.A., and Hoffmann, M.J. (2009). Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 19, 172-180.
35. Schwarzenbach, H., Alix-Panabieres, C., Muller, I., Letang, N., Vendrell, J.P., Rebillard, X., and Pantel, K. (2009). Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15, 1032-1038.
36. Steiner, I., Jung, K., Schatz, P., Horns, T., Wittschieber, D., Lein, M., Dietel, M., and Erbersdobler, A. (2010). Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiology 77, 260-266.
37. Sunami, E., Shinozaki, M., Higano, C.S., Wollman, R., Dorff, T.B., Tucker, S.J., Martinez, S.R., Singer, F.R., and Hoon, D.S. (2009). Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 55, 559-567.
38. Tang, P., Sun, L., Uhlman, M.A., Polascik, T.J., Freedland, S.J., and Moul, J.W. (2010). Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer 116, 4711-4717.
39. Thierry, A.R., Mouliere, F., Gongora, C., Ollier, J., Robert, B., Ychou, M., Del Rio, M., and Molina, F. (2010). Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 38, 6159-6175.
40. Tost, J., and Gut, I.G. (2007). DNA methylation analysis by pyrosequencing. Nat Protoc 2, 2265-2275. (Pubitemid 351575045)
41. Veeck, J., and Esteller, M. (2010). Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 15, 5-17.
42. Yegnasubramanian, S., Haffner, M.C., Zhang, Y., Gurel, B., Cornish, T.C., Wu, Z., Irizarry, R.A., Morgan, J., Hicks, J., DeWeese, T.L., Isaacs, W.B., Bova, G.S., De Marzo, A.M., and Nelson, W.G. (2008). DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68, 8954-8967.
43. Yegnasubramanian, S., Kowalski, J., Gonzalgo, M.L., Zahurak, M., Piantadosi, S., Walsh, P.C., Bova, G.S., De Marzo, A.M., Isaacs, W.B., and Nelson, W.G. (2004). Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64, 1975-1986. (Pubitemid 38339443)